Welcome to our dedicated page for Evaxion Biotech A/S news (Ticker: EVAX), a resource for investors and traders seeking the latest updates and insights on Evaxion Biotech A/S stock.
Evaxion Biotech A/S (EVAX) is a clinical-stage biotechnology company leveraging proprietary AI platforms to advance immunotherapies for cancer and infectious diseases. This page serves as the definitive source for verified corporate announcements, research milestones, and strategic developments.
Investors and industry observers will find timely updates on clinical trial progress, regulatory filings, and technology innovations. Our curated collection includes press releases on AI-driven drug discovery, partnership announcements, and financial reports, all organized for efficient tracking of the company's trajectory.
Key content areas include updates from Evaxion's PIONEER and EDEN platform pipelines, oncology vaccine developments, and infectious disease research breakthroughs. The repository is maintained to reflect the company's evolving position at the intersection of artificial intelligence and immunotherapy.
Bookmark this page for streamlined access to Evaxion's official communications. Check regularly for new developments in personalized cancer vaccines and AI-optimized antigen discovery.
Evaxion Biotech (Nasdaq: EVAX) announced the acceptance of a scientific paper at ICML 2021. The paper, titled “Efficient Generative Modelling of Protein Structure Fragments using a Deep Markov Model,” presents BIFROST, a predictive system that converts sequence data into protein structure information, aiding drug and vaccine design. BIFROST's Bayesian approach improves the reliability of predictions, making it suitable for drug development with incomplete datasets. The company aims to integrate these advancements into its AI platforms for enhanced vaccine development.
Evaxion Biotech A/S (NASDAQ: EVAX) announced new preclinical data from its AICoV program, aimed at developing next-generation vaccines against coronaviruses. Utilizing the RAVEN AI platform, the program identifies novel immunogenic T cell epitopes beyond the spike protein, enhancing vaccine design against variants. Key advantages include overcoming variant effectiveness issues and eliminating cold storage needs. Initial animal studies showed promising immune responses comparable to human sera. The AICoV initiative receives support from international investors and Innovation Fund Denmark.
Evaxion Biotech (NASDAQ: EVAX) announced the election of Lars Holtug to its Board of Directors during the Annual General Meeting on May 25, 2021. Holtug, a seasoned financial professional with extensive experience in the healthcare sector, will chair the Audit Committee, succeeding Helen M. Boudreau. Chairwoman Marianne Søgaard expressed confidence that Holtug's background in the biotech industry and his past roles, including at PwC, will be beneficial as Evaxion progresses its clinical programs targeting cancer and infectious diseases.
Evaxion Biotech A/S (NASDAQ: EVAX) announced its Q1 2021 financial results, reporting cash reserves of $27 million as of March 31, 2021. Following a successful IPO raising $30 million, Evaxion is advancing its lead product candidates, EVX-01 and EVX-02, with Phase 1/2a data expected late Q2 2021. R&D expenses increased to $3.9 million, reflecting growth in clinical trials and staffing. The company reported a net loss of $4.1 million for the quarter. Overall, the financial position supports continued development of key programs and a cash runway extending into 2022.
Evaxion Biotech (NASDAQ: EVAX) will present its Q1 2021 financial results on May 13, 2021. CEO Lars Wegner and CFO Glenn Vraniak will lead an earnings call at 8:30 a.m. EDT. Dial-in numbers: US: 877-407-0792, International: +1-201-689-8263, Conference ID: 13718732. An audio webcast will be available on Evaxion's website. The company develops AI-driven immunotherapies targeting cancer and infectious diseases, with a pipeline including three patient-specific cancer treatments currently in Phase 1/2a trials.
Evaxion Biotech (Nasdaq: EVAX) announced a significant presentation by Dr. Jens Kringelum at the 4th Neoantigen Summit Europe, focusing on AI's role in personalized cancer medicine. The discussion highlighted advancements in predicting cancer neoepitopes using peptide-MHC complex stability. Evaxion's AI platform, PIONEER, is continuously evolving, leveraging new methods for enhanced immunotherapy design. CEO Lars Wegner emphasized the efficiency gains in drug development from these improvements. The company is developing a range of patient-specific immunotherapies and vaccines to address bacterial and viral infections.
Evaxion Biotech A/S (Nasdaq: EVAX) reported strong progress in its Q4 and full year 2020 results, highlighted by a successful IPO in February 2021 that raised $30 million. The company has cash reserves of $5.8 million as of Dec 31, 2020, which have been bolstered by IPO proceeds, ensuring funding into 2022. Clinical trials for their cancer vaccine EVX-02 are on track, with anticipated data releases in Q2 2021. However, the company reported a net loss of $15 million for 2020 with increased R&D and administrative expenses compared to the previous year.
Evaxion Biotech A/S (Nasdaq: EVAX), a clinical-stage biotechnology firm, will announce its 2020 financial results on April 6, 2021. CEO Lars Wegner and CFO Glenn Vraniak will lead an earnings call at 8:30 a.m. EDT. Evaxion specializes in AI-driven immunotherapies targeting cancer and infectious diseases, with a pipeline that includes three patient-specific cancer immunotherapies in development and a preclinical vaccine program against S. aureus, including MRSA. Interested parties can access dial-in and webcast details through provided links.
Evaxion Biotech A/S (NASDAQ: EVAX) announced a publication in Scientific Reports, detailing a collaborative study with the University of Southern Denmark on S. aureus infections. The study utilized dual RNA sequencing to explore host-pathogen interactions, revealing insights into the bacterium's virulence factors. CEO Lars Wegner highlighted the importance of these findings for developing targeted vaccines via Evaxion's EDEN AI platform. The company is advancing a portfolio of immunotherapies and vaccines, including a program against S. aureus infections.
Evaxion Biotech (Nasdaq: EVAX) has opened a new corporate headquarters and research facility in the DTU Science Park, Hoersholm, Denmark. This facility consolidates its diverse operations from Denmark and Italy under one roof, designed to foster collaboration among bioinformaticians and clinical teams. The 60-employee-capacity site will support ongoing research and future expansions. CEO Lars Wegner highlighted that this move aims to enhance the development of AI-driven immunotherapies targeting cancer and infectious diseases, with current projects in various clinical stages.
